EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings.
Saved in:
| Title: | EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings. |
|---|---|
| Authors: | Crawford, S1 (AUTHOR), Li, H1 (AUTHOR), Srivastava, B1 (AUTHOR), Martin, P2 (AUTHOR), Gahn, J2 (AUTHOR), Rogers, KA3 (AUTHOR) |
| Source: | Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS74-S74. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10983015 |
|---|---|
| DOI: | 10.1016/j.jval.2024.03.391 |
